SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for...
Hence then, the article about halozyme announces fda approval of argenx s vyvgart hytrulo prefilled syringe co formulated with enhanze for self injection for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy )
Also on site :
- 'Love on the Spectrum' Star Abbey Romeo Tasting Banana Foster at the Celebrity Chef Gala Is Every Millennial Ever
- BLUETTI Showcases Integrated PAYGO Energy Solution at Canton Fair, Expanding Partnership Opportunities in Africa
- Sandra Bullock Shares Thoughts on AI and Says ‘We Have to Make It Our Friend’ and ‘Lean Into It’